NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $20.23 +0.26 (+1.30%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$19.30▼$20.4450-Day Range$13.09▼$20.8352-Week Range$9.93▼$21.48Volume1.41 million shsAverage Volume414,393 shsMarket Capitalization$1.18 billionP/E Ratio14.99Dividend Yield2.97%Price Target$23.00Consensus RatingModerate Buy Company OverviewEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More… Embecta Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 76% of companies evaluated by MarketBeat, and ranked 205th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingEmbecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEmbecta has only been the subject of 2 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.15% Earnings GrowthEarnings for Embecta are expected to grow by 9.15% in the coming year, from $2.84 to $3.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 14.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 14.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.67.Price to Earnings Growth RatioEmbecta has a PEG Ratio of 1.08. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.28% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldEmbecta pays a meaningful dividend of 3.00%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 19.35% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.28% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.65 News SentimentEmbecta has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Embecta this week, compared to 3 articles on an average week.Search Interest6 people have searched for EMBC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Embecta to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News Headlinesembecta to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 19 at 5:00 PM | globenewswire.comEmbecta (NASDAQ:EMBC) and PAVmed (NASDAQ:PAVM) Critical AnalysisDecember 14, 2024 | americanbankingnews.comDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."December 21, 2024 | Banyan Hill Publishing (Ad)Contrasting Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ)December 13, 2024 | americanbankingnews.comBTIG upgrades Embecta Corporation (EMBC) to a BuyDecember 11, 2024 | markets.businessinsider.comHere Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. (EMBC)December 9, 2024 | msn.comNew Initiatives Expected To Make Embecta More ProfitableDecember 4, 2024 | seekingalpha.comEmbecta Corp Appoints Anthony Roth as VP and CAODecember 2, 2024 | tipranks.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC stock has increased by 6.9% and is now trading at $20.23. View the best growth stocks for 2024 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) announced its earnings results on Tuesday, November, 26th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.05. The company's revenue was up 1.5% compared to the same quarter last year. Who are Embecta's major shareholders? Embecta's top institutional investors include River Road Asset Management LLC (6.03%), Yacktman Asset Management LP (4.38%), FMR LLC (4.17%) and State Street Corp (4.00%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings11/26/2024Ex-Dividend for 12/18 Dividend12/06/2024Dividend Payable12/18/2024Today12/20/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$26.00 Low Stock Price Target$20.00 Potential Upside/Downside+13.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.35 Trailing P/E Ratio14.99 Forward P/E Ratio7.12 P/E Growth1.08Net Income$78.30 million Net Margins6.97% Pretax Margin3.94% Return on Equity-18.54% Return on Assets11.43% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio1.58 Sales & Book Value Annual Sales$1.12 billion Price / Sales1.05 Cash Flow$3.39 per share Price / Cash Flow5.97 Book Value($12.80) per share Price / Book-1.58Miscellaneous Outstanding Shares58,131,000Free Float57,540,000Market Cap$1.18 billion OptionableOptionable Beta1.25 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:EMBC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.